Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

Therapy directed against oncogenic FLT3 has been shown to induce response in patients with acute myeloid leukemia (AML), but these responses are almost always transient. To address the mechanism of FLT3 inhibitor resistance, we generated two resistant AML cell lines by sustained treatment with the F...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindblad, O, Cordero, E, Puissant, A, Macaulay, L, Ramos, A, Kabir, N N, Sun, J, Vallon-Christersson, J, Haraldsson, K, Hemann, M T, Borg, Å, Levander, F, Stegmaier, K, Pietras, K, Rönnstrand, L, Kazi, J U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399143/
https://www.ncbi.nlm.nih.gov/pubmed/26999641
http://dx.doi.org/10.1038/onc.2016.41

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399143/
https://www.ncbi.nlm.nih.gov/pubmed/26999641
http://dx.doi.org/10.1038/onc.2016.41

Ejemplares similares